Big Breakthrough in Anti-Cancer Market: New Anti-Cancer Drug Can Enhance Individual’s Immunity by Affecting only Cancer Cells
Traditional drugs are known to attack and kill cancer cells directly; in contrast, anti-cancer immunotherapy kills cancer cells by solidifying the body’s immunity. It is a unique form of treatment against cancer that has started to come into the limelight in recent years. However, anti-cancer immunotherapy is only applicable for a minority of cancer patients who have some degree of immunity in them from the start. Recently, a cancer treatment drug by the name of doxorubicin has proved to enhance a patient’s immune response via various components that it releases once cancer cells are killed. But the problem is that inflammatory and toxicity responses led by 'doxorubicin' can also affect normal cells while doing their work against cancer cells. This effect can lower an individual’s immunity levels which makes the immunotherapy less effective.
A research team might have been able to tackle this issue by developing an anti-cancer pro-drug with the ability to improve anti-cancer immunotherapy. The breakthrough is set to bring a great boost to the Anti-Cancer Market as the new pro-drug only affects the cancer cells, thus, compressing the toxicity to normal cells as well as immune cells. In the end, it would be able to enhance an individual’s immunity in a way that wasn’t possible before.
The new anti-cancer drug targets the cancer cells by successfully suppressing the resistance to 'doxorubicin' without causing any reaction within normal cells. It essentially utilizes the immunity-boosting potential of 'doxorubicin.' The pro-drug exhibits several anti-cancer effects when activated through abundant enzymes present inside cancer cells. These enzymes, however, are not present in normal cells, and so normal cells do not experience inflammatory and toxicity responses. Since only cancer cells are targeted now, there is a greater chance of increasing patient immunity via active anticancer immune response induced when 'doxorubicin' is activated.
The new drug was tested in non-clinical animal models wherein it proved to improve the anti-cancer immune response. Further, it also reduced the side effects associated with toxicity and inflammatory responses in normal tissue. Hence, evidence demonstrates that drug dosage can potentially increase the effectiveness of chemotherapy without the usual side effects.
It is important to raise the immunity level of patients beyond a certain level to provide remarkable therapeutic effects from immunotherapy. The anti-cancer drug could go a long way as it maintains the anti-cancer immune response of the drug. Furthermore, the development was accomplished using an already in clinical use drug, so the commercialization process for the discovery is also expected to be relatively straightforward and uncomplicated in terms of trials and mass production.
Other Related Reports:
Global Cancer Screening Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027
Global Platinum based Cancer Drug Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027
Global Pituitary Cancer Market 2021 by Company, Regions, Type and Application, Forecast to 2026
Global Cancer Supportive Care Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
Global Cancer Biological Therapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026